Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lymphoid reconstruction and vaccines.

Ronald E Gress1, Krishna V Komanduri, Hermann Einsele

  • 1Experimental Transplantation and Immunology Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA.

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|January 16, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma.

Haematologica·2021
Same author

Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.

British journal of haematology·2021
Same author

Novel molecular subgroups within the context of receptor tyrosine kinase and adhesion signalling in multiple myeloma.

Blood cancer journal·2021
Same author

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.

The Lancet. Oncology·2021
Same author

Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML.

Blood·2021
Same author

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

The New England journal of medicine·2021

Allogeneic hematopoietic stem cell transplantation (HSCT) offers robust treatment for blood cancers. Understanding immune recovery and T cell function post-HSCT allows for enhanced graft-versus-tumor effects while minimizing GVHD.

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • Allogeneic HSCT is a leading cell therapy for hematologic malignancies.
  • Donor lymphocytes are crucial for anti-tumor effects, infection control, and graft-versus-host disease (GVHD).

Purpose of the Study:

  • To review immune recovery kinetics after allogeneic HSCT.
  • To explore strategies for manipulating T cell repertoire to enhance graft-versus-tumor (GVT) effects and mitigate GVHD.

Main Methods:

  • Analysis of T cell subset recovery post-HSCT.
  • Utilizing molecular tools to track host versus donor cell populations.
  • Linking immunophenotype with immune cell function.

Main Results:

  • Detailed kinetics of donor-derived T cell recovery identified.

Related Experiment Videos

  • Insights gained into immune reconstitution post-allografting.
  • Demonstrated potential for immune system manipulation.

    • Conclusions:

    • Immune reconstitution after HSCT is a dynamic process.
    • Opportunities exist to actively shape T cell repertoire for improved therapeutic outcomes.
    • Selective augmentation of immune function can enhance GVT effects without increasing GVHD.